Detalhe da pesquisa
1.
Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus.
Antimicrob Agents Chemother
; 66(9): e0066922, 2022 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36005813
2.
Investigation of piperazine benzamides as human ß3 adrenergic receptor agonists for the treatment of overactive bladder.
Bioorg Med Chem Lett
; 27(4): 1094-1098, 2017 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28089699
3.
Discovery of benzamides as potent human ß3 adrenergic receptor agonists.
Bioorg Med Chem Lett
; 26(1): 55-9, 2016 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26590100
4.
Molnupiravir: Mechanism of action, clinical, and translational science.
Clin Transl Sci
; 17(2): e13732, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38593352
5.
Cerastecins inhibit membrane lipooligosaccharide transport in drug-resistant Acinetobacter baumannii.
Nat Microbiol
; 9(5): 1244-1255, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38649414
6.
Short-course empiric antibiotic therapy for possible early-onset sepsis in the NICU.
J Perinatol
; 43(6): 741-745, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36813903
7.
Short-course antibiotic therapy for pneumonia in the neonatal intensive care unit.
J Perinatol
; 43(9): 1145-1151, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37438484
8.
Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist.
Bioorg Med Chem Lett
; 21(8): 2330-4, 2011 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21439820
9.
Optimization of privileged structures for selective and potent melanocortin subtype-4 receptor ligands.
Bioorg Med Chem Lett
; 20(15): 4483-6, 2010 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20598533
10.
Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity.
Bioorg Med Chem Lett
; 20(22): 6524-32, 2010 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20933410
11.
Discovery of a spiroindane based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor agonist.
Bioorg Med Chem Lett
; 20(7): 2106-10, 2010 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20207541
12.
Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity.
Bioorg Med Chem Lett
; 20(15): 4399-405, 2010 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20598882
13.
Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.
J Med Chem
; 63(21): 12156-12170, 2020 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32633947
14.
Application of a Rat Liver Drug Bioactivation Transcriptional Response Assay Early in Drug Development That Informs Chemically Reactive Metabolite Formation and Potential for Drug-induced Liver Injury.
Toxicol Sci
; 177(1): 281-299, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32559301
15.
A trial comparing continuous positive airway pressure (CPAP) devices in preterm infants.
J Perinatol
; 40(8): 1193-1201, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32433510
16.
Evaluating the efficacy of Seattle-PAP for the respiratory support of premature neonates: study protocol for a randomized controlled trial.
Trials
; 20(1): 63, 2019 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30658678
17.
Quality Improvement Initiative to Reduce the Necrotizing Enterocolitis Rate in Premature Infants.
Pediatrics
; 137(5)2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27244778
18.
Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.
J Med Chem
; 59(24): 11039-11049, 2016 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28002958
19.
Discovery of Vibegron: A Potent and Selective ß3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.
J Med Chem
; 59(2): 609-23, 2016 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26709102
20.
Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist.
J Med Chem
; 45(21): 4589-93, 2002 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-12361385